Peter V. Sguigna

Cardiometabolic disease is associated with distinct proteomic signatures of acute disease activity in multiple sclerosis

Darin T. Okuda, Katy W. Burgess, Crystal Wright, Morgan C. Jones-McCreary et autres

Multiple sclerosis (MS) disease activity and treatment response may be influenced by systemic health factors, including cardiometabolic disease (CMD). This study evaluated how CMD influences inflammatory protein profiles and whether CMD modifies the effect of disease-modifying therapy (DMT). A retrospective study was …

us, fr (code pays fourni par la source)

Corrigendum to “Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis” [Clin. Immunol. 288 (2026) 110766]

Darin T. Okuda, Benjamin Anderson, Sophia M. Taylor, Morgan C. Jones-McCreary et autres

us (code pays fourni par la source)

Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis

Darin T. Okuda, Benjamin Anderson, Sophia M. Taylor, Morgan C. Jones-McCreary et autres

Multiple sclerosis (MS) is treated with branded or generic disease-modifying therapies (DMTs), with increasing concern for the composition and quality of off-patent products. Our objective was to evaluate differences in disease-specific biomarkers, a potential indicator of suboptimal therapeutic exposure, between individuals treated …

us (code pays fourni par la source)

Correction: Utility of Multi‑Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation

Darin T. Okuda, Tatum M. Moog, Morgan McCreary, Isabella Huddleston et autres

us (code pays fourni par la source)

Establishing humoral immunity to rabies in a person with multiple sclerosis through booster vaccination: A case report

D Dinov, P Hardeman, J Tessier, Peter V. Sguigna

It is known that certain disease-modifying therapies for multiple sclerosis impair humoral immunity; however, data on the effect of therapies on humoral immunity with human diploid cell rabies vaccine is limited. Here we present a case of a 31-year-old male with multiple …

us (code pays fourni par la source)

Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation

Darin T. Okuda, Tatum M. Moog, Morgan McCreary, Isabella Huddleston et autres

INTRODUCTION: Multiple sclerosis (MS) is a chronic neuroimmunological condition associated with acute relapses. Differentiating between acute symptom development related to autoimmune inflammatory demyelination versus pseudoexacerbation remains challenging. We aimed to evaluate the utility of a commercially available multi-analyte protein assay in (1) …

us (code pays fourni par la source)

Comparison of Pediatric Demyelinating Diseases using Axonal and Myelin-Sensitive MRI

Fang Frank Yu, Elayne Joe, Niloufar Saadat, Pallavi Srivastava et autres

BACKGROUND AND PURPOSE: Demyelinating diseases constitute the most frequent cause of non-traumatic neurological disability in the pediatric population. Conventional MRI, while sensitive to focal white matter injury, lacks specificity to discern between edema, demyelination and axonal loss. This study aimed to employ …

us (code pays fourni par la source)

Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation

Darin T. Okuda, Tatum M. Moog, Morgan Jones-McCreary, Isabella Huddleston et autres

us (code pays fourni par la source)

Clinical and radiological outcomes of directed treatment transitions from Gilenya ® to generic fingolimod

Mahi A. Patel, Tom G. Punnen, Kevin Shan, Morgan McCreary et autres

Background: Gilenya ® (fingolimod), a sphingosine-1-receptor agonist, is an effective treatment for multiple sclerosis (MS). However, increased relapse activity has been observed after transitioning to generic fingolimod despite prior prolonged disease stability. Objective: To quantify the clinical and radiological impact of transitioning …

us (code pays fourni par la source)

Selective Multi-Analyte Serum Protein Differences Between Gilenya and Generic Fingolimod in Multiple Sclerosis

Darin T. Okuda, Isabella Huddleston, Morgan McCreary, Katy W. Burgess et autres

us (code pays fourni par la source)

Why the disease modifying therapy transition? Investigating the reasons and clinical consequences in multiple sclerosis

Darin T. Okuda, Tom G. Punnen, Tatum M. Moog, Katy W. Burgess et autres

us (code pays fourni par la source)

Detection of Varicella Zoster Virus Reactivation in Cerebrospinal Fluid in Ischemic Stroke or Transient Ischemic Attack

Wenyang Li, Peter V. Sguigna, Chintan Rupareliya, Suriya Subramanian et autres

Background Epidemiological data suggest that the risk of ischemic stroke increases after varicella‐zoster virus (VZV) reactivation. The frequency of VZV reactivation in acute ischemic stroke (AIS) is unknown. The risk of recurrent stroke and the antiviral treatment effect, particularly in patients with …

us (code pays fourni par la source)